CL2015003761A1 - Derivados de etinil como antagonistas de receptor metabotrópico de glutamato. - Google Patents

Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.

Info

Publication number
CL2015003761A1
CL2015003761A1 CL2015003761A CL2015003761A CL2015003761A1 CL 2015003761 A1 CL2015003761 A1 CL 2015003761A1 CL 2015003761 A CL2015003761 A CL 2015003761A CL 2015003761 A CL2015003761 A CL 2015003761A CL 2015003761 A1 CL2015003761 A1 CL 2015003761A1
Authority
CL
Chile
Prior art keywords
receptor antagonists
metabotropic receptor
glutamate metabotropic
glutamate
ethinyl
Prior art date
Application number
CL2015003761A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Eric Viera
Heinz Stadler
Rainer E Martin
Daniel Ruener
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2015003761A1 publication Critical patent/CL2015003761A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPUESTOS DERIVADOS DE ETINILO Y SUS SALES, COMO ANTAGONISTAS DE RECEPTOR METABOTRÓPICO DE GLUTAMATO; SU PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DEL ANSIEDAD, DOLOR, DEPRESION, ENFERMEDAD DE PARKINSON, ENTRE OTRAS.
CL2015003761A 2013-07-08 2015-12-30 Derivados de etinil como antagonistas de receptor metabotrópico de glutamato. CL2015003761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13175535 2013-07-08

Publications (1)

Publication Number Publication Date
CL2015003761A1 true CL2015003761A1 (es) 2016-07-15

Family

ID=48745843

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003761A CL2015003761A1 (es) 2013-07-08 2015-12-30 Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.

Country Status (28)

Country Link
US (2) US9682959B2 (es)
EP (1) EP3019486B1 (es)
JP (1) JP6116761B2 (es)
KR (1) KR101767348B1 (es)
CN (1) CN105358543B (es)
AR (1) AR096824A1 (es)
AU (1) AU2014289398B2 (es)
BR (1) BR112015029724A2 (es)
CA (1) CA2914282A1 (es)
CL (1) CL2015003761A1 (es)
CR (1) CR20150650A (es)
DK (1) DK3019486T3 (es)
EA (1) EA027882B1 (es)
ES (1) ES2628206T3 (es)
HK (1) HK1215573A1 (es)
HU (1) HUE033270T2 (es)
IL (1) IL242682B (es)
MA (1) MA38659B1 (es)
MY (1) MY181847A (es)
PE (1) PE20160604A1 (es)
PH (1) PH12015502692A1 (es)
PL (1) PL3019486T3 (es)
SG (1) SG11201510607RA (es)
SI (1) SI3019486T1 (es)
TW (1) TWI527808B (es)
UA (1) UA116023C2 (es)
WO (1) WO2015004007A1 (es)
ZA (1) ZA201508410B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120309C2 (uk) * 2015-06-03 2019-11-11 Ф. Хоффманн-Ля Рош Аг Етинільні похідні
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
SG11202005361RA (en) 2017-12-14 2020-07-29 H Lundbeck As Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN153523B (es) * 1980-06-02 1984-07-21 American Cyanamid Co
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
AU2005336513B2 (en) * 2004-10-07 2012-08-09 Merck Sharp & Dohme Llc Thiazolyl mGluR5 antagonists and methods for their use
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CA2829171C (en) * 2011-04-26 2019-02-26 F. Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives
SI2702051T1 (sl) * 2011-04-26 2015-06-30 F. Hoffmann-La Roche Ag Etinilni derivati kot pozitivni alosteriäśni modulatorji mglur5
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5

Also Published As

Publication number Publication date
HUE033270T2 (en) 2017-11-28
US20160130255A1 (en) 2016-05-12
UA116023C2 (uk) 2018-01-25
AU2014289398A1 (en) 2015-11-26
CN105358543A (zh) 2016-02-24
JP2016523939A (ja) 2016-08-12
CR20150650A (es) 2016-01-11
ZA201508410B (en) 2017-08-30
SI3019486T1 (sl) 2017-07-31
TW201506019A (zh) 2015-02-16
IL242682B (en) 2018-11-29
EA201690162A1 (ru) 2016-05-31
EP3019486A1 (en) 2016-05-18
JP6116761B2 (ja) 2017-04-19
WO2015004007A1 (en) 2015-01-15
AR096824A1 (es) 2016-02-03
MA38659B1 (fr) 2016-10-31
ES2628206T3 (es) 2017-08-02
PH12015502692B1 (en) 2016-03-14
US9682959B2 (en) 2017-06-20
PH12015502692A1 (en) 2016-03-14
US9751856B2 (en) 2017-09-05
KR20160017026A (ko) 2016-02-15
PE20160604A1 (es) 2016-07-03
SG11201510607RA (en) 2016-01-28
KR101767348B1 (ko) 2017-08-10
CN105358543B (zh) 2018-06-12
CA2914282A1 (en) 2015-01-15
TWI527808B (zh) 2016-04-01
HK1215573A1 (zh) 2016-09-02
DK3019486T3 (en) 2017-06-19
EA027882B1 (ru) 2017-09-29
MA38659A1 (fr) 2016-02-29
BR112015029724A2 (pt) 2017-07-25
MY181847A (en) 2021-01-08
AU2014289398B2 (en) 2018-02-01
US20170217926A1 (en) 2017-08-03
PL3019486T3 (pl) 2017-08-31
EP3019486B1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2016001895A1 (es) Compuestos
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
ECSP19062381A (es) Moduladores del receptor de estrógeno
BR112017010402A2 (pt) carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
UY35947A (es) Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda